Nachrichten zur Immunic Inc. Aktie

Immunic adds new Chief People Officer ahead of Phase 3 readout

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has appointed Jaa Roberson as its first Chief People Officer, adding a senior human resources leader…

Immunic to present four vidofludimus calcium abstracts at MSToronto2026

Immunic Inc (NASDAQ:IMUX, FRA:10VA) said four abstracts on its lead MS drug candidate, vidofludimus calcium, have been accepted for presentation…

Immunic appoints Chitrang Davé as chief data and digital officer

Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it has appointed Chitrang Davé as chief data and digital officer, effective August 30, creating…

Immunic appoints Elena Ridloff to board of directors

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Elena Ridloff to its board of directors, the biotechnology company said Monday. Ridloff currently…

Immunic presents new vidofludimus calcium data at multiple sclerosis conference

Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consortium of Multiple Sclerosis Centers Annual…

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named biopharmaceutical executive Erik Lundgren as its chief executive officer as the company advances its…

Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout

Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed...…

Immunic advances Phase 3 MS program, eyes topline data by year-end

Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Wednesday it remains on track to deliver top-line phase 3 data for its lead…

Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Michael A. Panzara as Chief Medical Officer, bringing aboard a veteran neurologist with more…

Immunic to implement 1-for-10 reverse stock split

Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced it will implement a 1-for-10 reverse stock split of its common shares, effective April 27,…

Immunic appoints biopharmaceutical executive Jon Congleton to board

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has announced the appointment of veteran biopharmaceutical executive Jon Congleton to its board of directors, as…

Immunic secures European patent for MS drug candidate vidofludimus calcium

Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Tuesday the European Patent Office has granted a key patent covering dosing regimens for…

Immunic to present at healthcare investor conferences in March

Immunic Inc (NASDAQ:IMUX), a late-stage biotechnology company developing oral treatments for neurological and gastrointestinal diseases, will participate in...…

Immunic secures $400M to support late-stage MS trials

Immunic Inc (NASDAQ:IMUX) earlier this week outlined how a newly secured up to $400 million private placement is set to support…

Immunic sets stage for phase 3 MS data readout after $400M financing

Immunic Inc (NASDAQ:IMUX) said it is entering a pivotal period for its multiple sclerosis program after securing up to $400…

Immunic closes $200M private placement to fund late-stage MS trials

Immunic Inc (NASDAQ:IMUX) said on Tuesday it has closed a previously disclosed private placement financing, raising $200 million upfront with…

Immunic MS trial shows reduced brain lesions

Immunic Inc (NASDAQ:IMUX)’s chief medical officer Dr Andreas Muehler talked with Proactive about new data presented at the ACTRIMS Forum…

Immunic to raise up to $400M to fund late-stage MS trials, commercial push

Immunic Inc (NASDAQ:IMUX) announced that it has priced an oversubscribed private placement expected to generate up to $400 million in…

Immunic shares gain on $400M raise to fund late-stage MS trials, commercial push

Immunic Inc (NASDAQ:IMUX) announced that it has priced an oversubscribed private placement expected to generate up to $400 million in…

Immunic to present additional Phase 2 data on vidofludimus calcium in progressive MS

Immunic Inc (NASDAQ:IMUX) said it will present additional analyses from its Phase 2 CALLIPER trial of vidofludimus calcium (IMU-838) in…

Immunic targets MS market with Phase 3 data

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company’s major milestones in 2025 and key expectations…

Immunic looks to 2026 data as late-stage MS program advances

Immunic Inc (NASDAQ:IMUX) said on Wednesday it is entering a pivotal phase for its lead multiple sclerosis drug as the…

Immunic’s long-term treatment hope for multiple sclerosis

Immunic Inc (NASDAQ:IMUX) earlier this week highlighted the long-term clinical potential of its lead compound vidofludimus calcium in treating multiple...…

Immunic advances MS therapy vidofludimus calcium during Q3

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company’s third quarter highlights, with a particular focus…

Immunic CEO discusses MS focus, upcoming Phase 3 trial readouts

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company’s strong presence at BIO-Europe 2025 and the…

Immunic targeting mental and physical challenges facing MS patients

Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Dr Hella Kohlhof talked with Proactive about the company’s research focus on multiple sclerosis…

Immunic, Inc. (IMUX) Presents at The United European Gastroenterology (UEG) Congress UEG Week 2025 - Slideshow

…

Immunic highlights multiple sclerosis drug findings at key neurology gathering

Immunic Inc (NASDAQ:IMUX) has presented clinical trial data suggesting its oral therapy, vidofludimus calcium, could help slow disability in patients…

Immunic advances MS drug program with Phase 3 trials fully enrolled

Immunic Inc (NASDAQ:IMUX) said on Thursday it has fully enrolled its twin Phase 3 ENSURE trials for vidofludimus calcium, positioning…

Immunic CEO discusses Phase 2 multiple sclerosis study success

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about new positive data from the company’s phase 2 EMPhASIS…

Immunic reveals long-term data supporting potential of MS drug vidofludimus calcium

Immunic Inc (NASDAQ:IMUX) released new long-term data from an ongoing study showing that its experimental drug, vidofludimus calcium, continues to…

Immunic showcases MS drug data at BIO International Convention in Boston

Immunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio talked with Proactive about the company’s participation at the BIO International Convention...…

Immunic completes Phase 3 multiple sclerosis trial enrollment

Immunic Inc (NASDAQ:IMUX)’s chief medical officer Dr Andreas Muehler talked with Proactive about the successful completion of patient enrollment for…

Immunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trials

Immunic Inc (NASDAQ:IMUX) has announced the completion of enrollment for both phase 3 ENSURE trials of its lead asset, vidofludimus calcium…

Immunic raises $65M in public offering to fund clinical trials

Immunic Inc (NASDAQ:IMUX), a biotechnology firm focused on developing oral therapies for chronic inflammatory and autoimmune diseases, on Tuesday closed…

Immunic unveils pricing of $65M underwritten public offering

Immunic Inc (NASDAQ:IMUX) has announced the pricing of an oversubscribed underwritten public offering that is expected to generate approximately $65…

Immunic to raise up to $65M in underwritten public offering

Immunic Inc (NASDAQ:IMUX) has announced the pricing of an oversubscribed underwritten public offering that is expected to generate approximately $65…

Immunic reports reduced disability worsening in progressive multiple sclerosis trial

Immunic Inc (NASDAQ:IMUX) has reported promising results from its Phase 2 CALLIPER trial of vidofludimus calcium, which showed a 30%…

Immunic announces pricing of $5.1M direct offering to support clinical pipeline

Immunic Inc (NASDAQ:IMUX) has priced its $5.1 million registered direct offering led by Aberdeen Investments, selling 5.67 million shares at…

Immunic provides MS research update

Immunic Inc (NASDAQ:IMUX) earlier this week provided an update on its multiple sclerosis (MS) drug, vidofludimus calcium, highlighting its potential…

Immunic to highlight vidofludimus calcium’s potential as MS therapy at upcoming forum

Immunic Inc (NASDAQ:IMUX) announced that it will present key data for its investigational drug vidofludimus calcium in two poster presentations…

Immunic drug candidate may offer new obesity treatment

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive to discuss the company’s latest findings on IMU-856, a drug candidate…

Immunic highlights IMU-856’s potential as weight management therapy

Immunic Inc (NASDAQ:IMUX) has released new data that supports the potential of its investigational therapeutic IMU-856 as an oral treatment…

Immunic eyes transformative year ahead for MS therapy vidofludimus calcium

Immunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio joined Proactive to discuss the company’s progress in advancing its novel therapy...…

Immunic eyes key data readout from multiple sclerosis trial in 2025

Immunic Inc (NASDAQ:IMUX) has reflected on key milestones achieved in 2024, including advancing its novel therapy, vidofludimus calcium, toward key data...…

Immunics IMU-856 shows potential in gastrointestinal health trials

Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr. Andreas Muehler talked with Proactive about the publication of the company’s Phase 1 and…

Immunic reports positive Phase 1 results for celiac disease therapy published in The Lancet

Immunic Inc (NASDAQ:IMUX) announced that data from its phase 1/1b clinical trial for IMU-856, a small molecule targeting SIRT6, has…

Immunic, Inc. 2024 Q3 - Results - Earnings Call Presentation

…

Immunic highlights progress in multiple sclerosis programs, targets 2025 milestones

Immunic Inc (NASDAQ:IMUX) ended the third quarter with over $59 million in cash to advance its key clinical programs, including…

Immunic Inc. (IMUX): Studienupdate begeistert die Anleger - EF Hutton sieht 855 % Kurspotenzial!

Immunic Inc. (IMUX) ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von innovativen Therapien für chronische Entzündungserkrankungen und Autoimmunerkrankungen…